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Regenerative medicine as a  
disruptive technology: implications 
for manufacturing & clinical adoption
Geoffrey Banda, Joyce Tait & James Mittra
Although regenerative medicine has been described as a disruptive inno-
vation, there has been little critical enquiry into the nature and location 
of the disruption. This paper, based on ten cases in the UK, analyses the 
nature of disruption for allogeneic and autologous therapies in terms of 
manufacturing, distribution and adoption in clinical settings. We discuss 
the challenges of dealing with inherent variability in living systems and 
how this necessitates co-evolution of technologies and innovations. We 
propose that understanding of the distinction between disruptive and 
incremental innovation, and of the nature, extent and location of the dis-
ruption across sectoral value chains, can help to guide company innova-
tion strategies and government innovation support policies for regenera-
tive medicine, as already proposed for industrial biotechnology.
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INTRODUCTION
Regenerative medicine (RM), 
which promises to cure disease and 
respond to currently unmet medical 
needs [1], is frequently described 
as a ‘disruptive innovation’ [2,3]. 
However, there has been little crit-
ical enquiry into the nature and lo-
cation of the disruption, resulting 
in missed opportunities to shape 
the innovation ecosystem to make 
it more supportive of RM therapies. 
We have defined disruptive and 
incremental innovation as follows 
[4,5].
Disruptive innovation involves 
discontinuities in innovation path-
ways, requires new areas of research 
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and development (R&D), creation 
of new modes of production and/or 
new markets. It can lead to sectoral 
transformations and the displace-
ment of incumbent companies, or 
the creation of entirely new sectors, 
all with significant societal and 
economic benefits. There is often 
no pre-existing business model on 
which to build a strategy for dis-
ruptive innovation and there may 
also be a need to create a new value 
chain, or a new role for the emerg-
ing technology in an existing value 
chain. 
Incremental innovation fits well 
with the current business model 
of a firm. It generates competitive 
advantage and contributes to the 
economy through more efficient 
use of resources, or elimination of 
wasteful or environmentally dam-
aging practices, but will not lead to 
sectoral transformations.
This paper builds on the authors’ 
previous research [1,6,7]; providing 
new empirical data and analysis to 
inform our thinking on disruptive 
innovation and how the concept 
can be operationalized to deliver a 
more supportive policy environ-
ment [5]. The key to this approach is 
to attend to the extent of disruption 
of incumbent company business 
models, the location of that disrup-
tion within specific value chains, 
and the impact of regulatory and 
policy choices on the location and 
extent of disruption. Our case study 
of RM encompasses both allogeneic 
and autologous therapies:
Allogeneic therapies are developed 
by collecting cells from a donor, 
manipulating them to form a mas-
ter-cell bank, then using them as 
starting material to produce multi-
ple therapies administered to large 
numbers of patients, generating at-
tendant economies of scale. 
Autologous therapies are based on 
collection of cells from a patient, 
manipulation in the manufacturing 
environment and re-introduction 
into the same patient within a clin-
ical setting.
In line with the above defini-
tions, both allogeneic and autolo-
gous RM therapies are disruptive of 
the business models of incumbent 
small molecule pharmaceutical and 
bio-pharmaceutical companies [1], 
in that they require radically differ-
ent approaches to R & D, manufac-
turing, distribution and marketing. 
Autologous therapies, while equally 
disruptive of pharmaceutical busi-
ness models, could be regarded as a 
relatively incremental development 
for companies involved with organ 
transplants or for blood transfusion 
services (BTSs), albeit with some 
disruptive elements, given the na-
ture of the properties of the material 
being handled. 
The approach adopted in this 
paper contributes to understand-
ing where and to what extent au-
tologous and allogeneic therapies 
display disruptive or incremental 
innovation characteristics, based on 
original case study interviews with 
organizations involved in RM de-
velopment in the UK. It builds on 
our previous research to show how a 
disruptive/incremental lens can add 
insights that are valuable in devising 
policies to support the development 
of innovative technologies. 
BACKGROUND
Although there have been signifi-
cant advances in scientific knowl-
edge and understanding of RM, 
commercialization and large-scale 
production of autologous and al-
logeneic therapies have remained 
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challenging. For allogeneic thera-
pies, being developed in large scale, 
centralized manufacturing facilities 
[8], disruptive challenges include: 
the time and effort needed for do-
nor material collection, processing 
and storage in a bio-bank under 
current Good Manufacturing Prac-
tice (cGMP), followed by further 
processing to produce therapies for 
patients; cryopreservation of living 
material, safe distribution of frag-
ile living materials, ensuring trace-
ability of cells following treatment; 
and dealing with immunogenicity 
issues in recipient patients. Many 
of these factors also apply to autol-
ogous therapies being developed in 
localized manufacturing facilities, 
with additional challenges related 
to the personalized nature of the 
therapy, ruling out economies of 
scale. The Department of Business, 
Innovation and Skills (BIS) in 2011 
[9] suggested that manufacturing 
viable living cells for RM requires 
the development of “new technol-
ogies, tools and techniques” and, 
although considerable progress has 
been made, for example in manu-
facturing process development, RM 
therapy value chains are still a long 
way from delivering a reliable, prof-
itable route to market [10,11]. 
Lipsitz et al. argued that the 
new RM-related technologies span 
manufacturing, distribution sys-
tems, shelf life enhancement and 
automation (especially closed man-
ufacturing systems) [12]. This has 
led to further calls for advances in 
manufacturing and bio-processing, 
because of the non-scalability of 
existing technologies [9] and the 
need for skills development in the 
RM niche-focused areas. Abbasal-
izadeh et al. present a deeper anal-
ysis of the scientific, technological, 
and commercialization challenges 
of allogeneic therapies, suggesting 
that although autologous therapies 
are safer and often the preferred 
choice, they do not provide a sim-
ple off-the shelf product for clinical 
use [8]. They also argue that produc-
tion of autologous therapies is time 
consuming, skilled labor-intensive 
and, from an operational perspec-
tive, the mechanics of isolating 
cells and delivering the therapy are 
problematic for elderly and criti-
cally ill patients unable to tolerate 
biopsies. Lipsitz et al. demonstrate 
that lack of highly skilled labor is 
caused by current manufacturing 
process requirements and the costs 
incurred in training operators, in-
cluding routine validation of asep-
tic techniques for operators [12]. 
Additional issues include the need 
to independently verify batch re-
cord protocols, active working time 
delays due to suiting up procedures 
with laboratory garments, and the 
need for additional staff to facilitate 
gowning. The calls for ‘closed man-
ufacturing systems’ are based on the 
need to reduce some of these ‘neces-
sary redundancies’ of current clean 
room operation procedures for 
cGMP requirements. Other chal-
lenges include lack of value chain 
integration, technology delivery 
gaps, and arguably inappropriate 
or disproportionate governance of 
innovative technologies [4,6]. Given 
the disruptive nature of RM, new 
firm-to-firm linkages are needed to 
create new value chains and, during 
early development phases, broker-
age is important to create links with 
stakeholders [6]. These disruptive 
challenges are not experienced by 
manufacturers of small molecules 
and other biologicals and they are 
important for understanding the 
unique hurdles RM manufacturers 
face in assuring cellular product 
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safety, quality and efficacy, as well 
as traceability and attendant ethical 
considerations. 
Centralized & locally 
distributed manufacturing 
approaches
Harrison et al. argue that through-
out history there has been a steady 
shift from localized, decentralized 
production systems to centralized 
production systems, underpinned 
by the need to achieve economies of 
scale and scope [13]. Centralization 
was possible where manufacturers 
were dealing with standardized 
bulk products, which could be eas-
ily characterized and analyzed and 
were accompanied by increasingly 
automated processing and quality 
assurance systems. Lipsitz et al. ar-
gue that, for RM therapies, scalable 
production methods will determine 
the cost of goods sold, leading to the 
policy focus on allogeneic therapies 
because of their potential economies 
of scale and investment palatability 
making them slightly less disrup-
tive of incumbent pharmaceutical 
business models than autologous 
therapies [12]. However, allogeneic 
RM therapies are inherently dis-
ruptive of this centralizing trend 
because of the greater variability of 
biological inputs, creating technical 
difficulties in standardizing manu-
facturing and quality assurance and 
creating a need for close collabora-
tion between therapy producers and 
clinicians (see ‘RM manufacturing 
processes’, ‘The links between man-
ufacturing systems and distribution 
models’ and ‘Clinical adoption of 
autologous therapies’ sections). For 
these reasons, Harrison et al. foresee 
autologous therapies being man-
ufactured in locally distributed, 
‘near-hospital’ facilities [13]. This 
argument informs our focus on the 
nature and location of disruption in 
the development of RM therapies as 
it impacts on manufacturing, dis-
tribution and adoption in clinical 
settings. 
Given the challenges of producing 
autologous cell therapies, decentral-
ized or locally distributed manufac-
ture is the only feasible approach for 
autologous and gene-based cell ther-
apies. In response to BIS [9] and Ab-
basalizadeh et al. [8], Harrison et al. 
[13] argue that, as a result of recent 
advances in technologies that facil-
itate “reproducible, repeatable and 
reliable manufacture of highly spe-
cialist products at a small scale” and 
real-time monitoring Quality Man-
agement Systems (QMSs), it is in-
creasingly possible to move towards 
such locally distributed manufactur-
ing models. They also claim that this 
small scale, locally distributed tech-
nology approach makes it possible to 
handle “inherently unstable person-
alized cell and gene therapies”. 
Locally distributed manufacture 
of autologous cells will be an or-
der of magnitude more disruptive 
of the existing pharmaceutical and 
biopharmaceutical business mod-
els than current manufacturing 
approaches to allogeneic therapies, 
hence the lack of interest in these 
therapies by these incumbent sec-
tors. For allogeneic therapies, rath-
er than adaptation of the existing 
big pharma business model there 
is a need to develop new business 
models and value chains, involving 
new start-up companies or existing 
companies moving into health care 
from other sectors of the econo-
my (e.g., investment in manufac-
turing processes by Lonza and GE 
Healthcare). 
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The option for pharmaceutical 
companies to purchase locally dis-
tributed manufacturers of autolo-
gous cell therapies with a view to 
centralizing production does not 
exist, given the countervailing fac-
tors described above. Where such 
purchases have been attempted, 
cell therapy manufacturers have 
been frustrated by the lack of un-
derstanding of the acquiring firms 
about how RM works and how the 
feasible business models are differ-
ent from the small or bio-molecule 
contexts investors are accustomed 
to. This is a common experience 
where incumbent large companies 
attempt to take on disruptive tech-
nologies. Given these constraints on 
investment the Advanced Therapies 
Manufacturing Action Plan [14] 
called for systemic investment in 
the sector to engender a more com-
petitive fiscal environment.
Clinical adoption of 
allogeneic & autologous 
therapies
Manufacturing challenges are not 
the only factor limiting the devel-
opment and hence the adoption of 
RM therapies. We previously not-
ed a lack of co-operation between 
manufacturers and clinicians affect-
ing the adoption of RM therapies 
[6], a view supported by Gardner et 
al. who observed that RM products 
will need to “work hard to create an 
adoption space” in current health-
care settings [15]. 
Also, prevailing regulatory sys-
tems for RM therapies, along with 
other governance mechanisms 
such as the establishment of shared 
standards, have not been suffi-
ciently adapted to meet the needs 
of centralized or locally distributed 
manufacturing systems and per-
sonalized delivery to patients. RM 
therapies are also disruptive on 
current regulatory frameworks be-
cause of the introduction of meth-
ods beyond minimal manipulation 
and raw materials that are outside 
current supply chains for transfu-
sion and transplantation. These 
questions are not dealt with here 
but have been addressed elsewhere 
[1]. Faulkner has also identified the 
challenges of “opposing forces for 
gatekeeping and innovation” by 
regulators of manufacturing and 
clinical practices [16]. We have 
also argued that accelerating clin-
ical adoption is dependent on the 
creation of innovation ecosystems 
that promote rapid integration of 
RM and allied business models as 
well as creating an environment 
where new business models are 
given a chance to thrive [6,17]. We 
have previously argued that the 
public-private interaction by inno-
vation broker institutions such as 
the Cell and Gene Therapy Cata-
pult are critical in the early phases 
of building supportive innovation 
ecosystems as they bridge value 
chain gaps, and de-risk early de-
velopment stages [6]. This earlier 
work contributes to the frame de-
scribed here to support analysis of 
the disruptive nature of RM thera-
pies and the impact on: collabora-
tion among clinicians, the clinical 
prescription system and hospital 
administrative systems; the via-
bility of manufacturing processes; 
challenges related to ordering, stor-
ing and re-thawing therapies; and 
finally clinical adoption. We are 
aware that pricing and cost effec-
tiveness are linked to manufactur-
ing and clinical adoption, however 
we do not focus on them in this 
paper.
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METHODOLOGY
We used the case study approach 
advocated by Yin for carrying out 
an empirical enquiry of issues that 
are embedded in real-life contexts 
[18]. In line with the argument by 
Stake we considered the complex-
ity of the cases to understand the 
circumstances, contexts and other 
dynamics of the interactions of the 
organizations and actors we investi-
gated [19]. We chose the case study 
approach because we were interested 
in the ‘how and why questions’ and 
the broader situational context with-
in which these technologies are be-
ing developed. 
Using a purposive sampling 
method, we approached 20 RM 
companies/organizations involved 
in RM-related activities in the UK 
and gained access to 10 of them. 
We conducted 18 semi-struc-
tured interviews (ten completed in 
2014/15, with follow-up interviews 
in 2015/16). Semi-structured inter-
views allowed us the flexibility to 
follow themes and interesting leads 
that arose during the interview itself. 
After seeking informed consent, the 
interviews lasted between 1 and 2 
hours and were audio-recorded and 
transcribed verbatim. Using manu-
al thematic coding, we identified a 
number of salient themes, some of 
which are the focus of discussion 
in this paper. We used the STRA-
TIS methodology to understand the 
business models, innovation ecosys-
tems and value chains in the sector 
[20]. 
This paper also draws on our re-
search on Proportionate and Adap-
tive Governance of Innovative Tech-
nologies [4], which has refined our 
thinking on the important features 
of, and differences between, disrup-
tive and incremental innovations.
MANUFACTURING & 
CLINICAL ADOPTION 
OF RM THERAPIES: 
INTERVIEWEE 
PERSPECTIVES
Our analysis showed that allogene-
ic therapies are disruptive of many 
aspects of the business models of in-
cumbent pharmaceutical firms, giv-
en the challenges involved in large 
scale manufacturing of cellular prod-
ucts, the storage and distribution of 
living materials, and delivery to very 
different markets. Large companies 
developing bio-pharmaceuticals will 
have overcome some, but not all of 
these disruptive challenges. Phar-
maceutical companies’ adherence 
to current business models, despite 
these disruptive features of alloge-
neic therapies, have led them to 
persevere in developing large scale, 
centralized manufacturing facili-
ties, designed to deliver a commod-
itized product internationally to 
large numbers of patients, in order 
to make RM therapies an attractive 
investment proposition. This has be-
come the dominant expected future 
business model for RM therapies, in 
the process side-lining the develop-
ment of autologous therapies, which 
are much less capable of achiev-
ing compatibility with the current 
business models of pharmaceutical 
companies.
The following sub-sections use 
our interview data to reflect on issues 
related to the disruptive nature of 
cell-based therapies.
Raw material sourcing 
The challenge of inherent 
variability in living systems 
A factor acknowledged in the litera-
ture, and confirmed by respondents 
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in all ten of our cases, is the com-
plexity of working with raw ma-
terials composed of living systems 
which, unlike small molecules 
(Figure 1, left hand side), are diffi-
cult to standardize (Figure 1, right 
hand side). Specifically, the disrup-
tive nature of RM first, emanates 
from these perspectives: RM raw 
materials cannot be subjected to 
traditional sterilization techniques 
and therefore need aseptic process-
ing methods; second, because the 
therapy is integrated into the body 
unlike drugs which are metabolized 
and expelled, pharmacokinetics and 
pharmacodynamics are challeng-
ing; and third there is a need for 
defining, effecting and monitoring 
quality spanning the manufacturing 
and clinical phases. A respondent 
from a contract manufacturing or-
ganization reported that the private 
sector tends to play to its strengths 
by focusing on the “manufacturing 
piece because that’s closer to what a 
standard pharmaceutical company 
would do”, which covers raw ma-
terial sourcing and processing. This 
implies that incumbent pharmaceu-
tical companies, faced with a dis-
ruptive new technology, lock into 
what they already know and create 
an element of path dependency to 
make a disruptive transition more 
feasible. A disruptive element of the 
transition to RM for a conventional 
pharmaceutical company includes: 
incompatibility with chemical enti-
ties that can be easily standardized 
and produced in bulk and, because 
of chemical stability, intermediate 
and finished products can be stored 
for long periods with no need to 
identify the donor. Supporting 
these observations, he added: 
“Here you have a product 
which has been derived from 
a human being, so it has all 
that … inherent biological 
variability, or even [a cell] 
derived from me on two 
different occasions, it can 
behave in a different kind of 
way. The cell obviously is a 
living system in its own right 
… it’s a living system in vitro 
and then it’s also a living 
system when you put it into 
the patient. So, like all living 
systems it has a nasty habit 
of doing its own thing.” – 
Managing Director, RM firm 
in research and development 
and contract manufacturing.
Other respondents acknowl-
edged that they still do not fully 
understand the cell’s mechanism of 
action, having observed that cellular 
therapeutics work best when differ-
ent types of cells are used in com-
bination. So significant interactions 
between the different types of cell 
or tissue seem to be important for a 
functioning therapy. This is in con-
trast to small molecules and other 
biologicals where the biochemical 
pathways and pharmacokinetics 
end point are well known. Thus, 
for allogeneic therapies, innovators 
need to solve the challenge of stan-
dardizing and automating develop-
ment processes for therapies with 
inherent variability, and to convince 
regulators of the robustness of their 
approach, especially for therapies 
that become integrated into the 
body. Furthermore, a product man-
ufactured in the USA under FDA 
conditions cannot be assumed to 
be identical to a product manufac-
tured in Europe under European 
cGMP conditions, according to 
respondents in our study. This cre-
ates manufacturing and regulatory 
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compliance challenges for firms 
operating across geographical re-
gions with different regulatory sys-
tems, for example Europe, Asia and 
the USA. This has implications for 
validation and quality assurance 
processes across different manufac-
turing facilities for the same firm, 
making centralized manufacturing 
more problematic, and forcing firms 
into locally decentralized or locally 
distributed manufacturing, illus-
trating the disruptive impact. Given 
that large scale manufacturing by 
the same firm across different coun-
tries needs to comply with different 
national regulatory requirements, 
it is difficult to move employees in 
regulatory interfacing jobs across 
different countries, and it also mul-
tiplies the complement of regulato-
ry personnel in the company com-
pared to centralized manufacturing. 
This phenomenon affects both au-
tologous and allogeneic therapies 
and impacts the whole process from 
donor selection to therapy deliv-
ery. Autologous therapies have an 
additional staffing burden where 
the manufacturing system is locally 
distributed.
The need for close 
collaboration between RM 
firms & the clinic
Another feature of the disruptive 
nature of RM development for 
 f FIGURE 1
The contexts where regenerative medicine is disruptive of incumbent manufacturing, distribution and 
clinical adoption systems.
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conventional drug production is 
the intricate collaboration required 
between manufacturers and, for ex-
ample, the National Health Service 
(NHS) in the UK, for sourcing cells 
or tissue, and manufacturing (Figure 
1 last box on the right). For a tissue 
regeneration case the respondent 
noted (Figure 3): 
“…There is need in the UK 
to collaborate with the NHS 
for cadaver identification, 
followed by organ harvesting 
leading to transport of the 
organ to a specialist de-
cellularization facility and 
adequate storage of frozen 
samples.” Respondent from a 
Tissue Regeneration Firm.
The NHS is critical for sourc-
ing organs and, for some therapies, 
there is a need for the NHS to link 
up with manufacturers to collect 
cells from the patient for seeding 
a bio-matrix pre-surgery. This en-
tails aligning work scheduling for 
manufacturing with patients’ clin-
ical visits. Such complex manufac-
turer-clinic interactions are an ad-
ditional disruptive element beyond 
what is necessary for conventional 
drug or biopharmaceutical treat-
ments. It requires RM firms to 
invest in specific RM technology 
delivery skills and training for phar-
macists, specialist nursing staff, sur-
geons and technical/administrative 
supporting functions, including 
engineering and procurement. This 
also has important staffing and cost 
management implications for local 
NHS trusts, which are managed 
differently across the UK, affecting 
the ease of adoption into clinical 
practice.
RM manufacturing 
processes
Both allogeneic and autologous 
therapies are, or would be, dis-
ruptive of incumbent firms’ small 
 f FIGURE 2
The technical processes involved in clinical adoption of an autologous therapy such as CAR-T Cell.
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molecule or biopharmaceutical 
companies on manufacturing pro-
cesses, including the quality assur-
ance techniques related to dealing 
with living cells which are inherent-
ly variable and difficult to standard-
ize. However, allogeneic therapies 
can be scaled up (implying an incre-
mental aspect), whereas autologous 
therapies cannot, although they can 
be scaled-out. The attraction of scale 
up, critical for building economies 
of scale for allogeneic therapies, is 
its similarity with manufacturing 
stages of conventional pharma busi-
ness models, something investors 
in the sector are familiar with. A 
respondent from a firm specializing 
in allogeneic therapies reflected the 
scale up aspect as a key factor for 
their firm.
 “… our [allogeneic] 
technology approach 
really gives us the ability 
to generate lots and lots 
of doses… And it makes 
an allogeneic approach, 
perhaps, more achievable. 
Our cells are non-
immunogenic, so they don’t 
suffer the rejection problems 
that might be seen typically 
with an allogeneic approach.” 
– Senior Executive for Cell 
Therapy Manufacturing Firm 
A.
For blood and tissue services, RM 
innovation is more incremental, as 
key processes such as raw material 
sourcing, manipulation and storage, 
and traceability requirements are 
already routine in the sector. How-
ever, there is lack of cross-sectoral 
knowledge about different therapy 
areas. Respondents in our study 
acknowledged that skills tend to 
be niche-focused and scarce in the 
industry, especially in development 
and translational activities. This has 
implications for business continui-
ty and the need for emerging firms 
to retain staff, especially given the 
close linkages between the firms and 
the NHS.
The need for co-evolution of 
technologies & innovations
For some allogeneic therapies in-
volving for example gene therapy or 
immunotherapy, our study revealed 
the need for close interactions be-
tween therapy developers, technol-
ogy suppliers and the clinic. The 
link between the technology suppli-
er and the clinic is also required for 
locally distributed manufacturing 
systems or in/near-hospital man-
ufacturing systems as part of the 
collaboration between the therapy 
developer and the NHS.
A key challenge raised for thera-
py developers was the need either to 
re-purpose existing technology or to 
design new technologies for manu-
facturing and quality assurance of 
therapies, as highlighted here:
“…when people are making 
… protein therapeutics, 
which is the other large-scale 
culture technology, they 
don’t want to keep the cells. 
They’re deliberately breaking 
the cells up and trying to 
recover the protein out of 
them. We’re doing exactly 
the opposite, we’re trying 
not to damage the cells and 
get rid of everything else. So 
there is no technology out 
there at the moment that has 
been developed specifically 
for large scale cell recovery.” 
– Senior Executive RM 
Collaborative Project 
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This firm was attempting to re-
cover intact cells from culture, and 
there was no technology on the 
market at the time capable of that 
function. They reached out to their 
collaborators and their suppliers to 
design equipment capable of har-
vesting intact cells and considerable 
progress is now being made in this 
area, relevant to both autologous 
and allogeneic therapies [21]. This 
also happened for two other cas-
es, where the in-house developers 
worked with their suppliers to de-
sign equipment for their manufac-
turing needs. 
Respondents from organizations 
developing allogeneic therapies also 
acknowledged the need for closer 
interaction with the clinical setting 
for cell harvesting and therapy de-
livery and, by implication, the de-
sign and operability of technologies 
and operations used by the clini-
cians. An additional collaboration 
that emerged is the triad of therapy 
developers, contract manufacturers 
and technology developers, espe-
cially during therapy development 
optimization stages. The triad is 
important as technology optimiza-
tion costs are borne by the therapy 
developer, which in most cases is 
resource constrained. Over time the 
triad is likely to morph into a dyad 
(therapy developer-contract man-
ufacturer) especially in cases where 
a market authorized therapy is con-
tract manufactured for the lead firm 
in another geographical location, in 
which case the contract manufac-
turer works closely with the clinical 
setting.
Challenge of specialized skills
A 2011 study by BIS highlighted the 
challenge bioprocessing units faced 
in recruiting and retaining skilled 
staff for manufacturing, quality 
management, validation and batch 
release [9]. Our study confirmed 
these earlier findings, and our re-
spondents reported that because of 
the niche focus of the technologies, 
training a person takes time and 
money, so it is important that those 
skills are retained. 
The links between 
manufacturing systems & 
distribution models 
Table 1 summarizes the expected 
manufacturing processes and likely 
distribution challenges faced by the 
ten cases we studied. At the time of 
the study none of the organizations 
had a market authorized product, 
and six therapy developers were at 
various stages of clinical testing. 
Our study suggests that orga-
nizations are likely to favor cen-
tralized manufacturing for two 
reasons; skills shortages and infra-
structure requirements for resource 
constrained SMEs that have to deal 
with infrastructural, technological, 
organizational, governance, val-
ue chain and regulatory hurdles 
when they are at a cash burn phase 
of development. Unless there are 
significant injections of cash, the 
locally distributed manufacturing 
approach may take time especially 
given the cost of setting up cGMP 
plants to manufacture clinical grade 
cell therapies. With dependence 
on central manufacturing come 
the challenges of cryopreservation 
and efficient distribution systems. 
Furthermore, this imposes an in-
vestment challenge for the clinic 
in terms of acquiring the cryo-
preservation infrastructure, and 
thawing therapies correctly just be-
fore use. These administrative and 
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technological challenges are key 
impacts of innovative technologies 
especially on resource constrained 
SMEs with no prior interaction 
with the health system.
Clinical adoption of 
autologous therapies
In this section we present two ex-
amples: autologous immunothera-
py (Figure 2) and autologous tissue 
engineering based on a donated ca-
daveric processed biomatrix, where 
therapy delivery involves surgery 
(Figure 3). We focus on the techni-
cal issues of therapy delivery, and 
not on re-imbursement, which oth-
ers have already covered in some 
depth. Compared to incumbent 
biopharmaceutical and traditional 
pharma models of therapy delivery, 
there will need to be close linkages 
between the hospital, manufactur-
ers, and logistics firms. Condition 
diagnosis will not be different from 
current practice but an autologous 
therapy departs from convention-
al treatments in the prescription, 
requirement for work scheduling, 
and timing the collection of cells 
or biopsy with the work schedule 
in the cell manufacturing facility. 
The cell manufacturing plant also 
needs to align its production and 
delivery times with the time the pa-
tient has been booked to be at the 
hospital. Behind all these activities 
are numerous administrative tasks 
for the manufacturer, logistics firm 
and the hospital that are disruptive 
of the business model of a biotech 
or pharmaceutical firm. For blood 
transfusion services, already dealing 
with living materials, these logistic 
and administrative issues are closer 
to being incremental, although the 
challenges of clinical grade manu-
facturing of cells in bulk for therapy 
also include elements of disruption, 
albeit with a narrower gulf in skills 
 f FIGURE 3
The technical processes involved in tissue regeneration combining donated cadaveric organ and autolo-
gous cells delivered through surgery.
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than for mainstream biotech and 
pharma companies.
Our second example, Figure 3, 
highlights the complex process-
es that need to be aligned when 
dealing with an organ transplant 
using autologous cells seeded on 
a donated organ. There would be 
a need to work closely with the 
NHS to identify organ donors and 
upon their death collect the organ 
while it is still viable. The organ 
would be processed to remove the 
cells of the donor and placed in 
cold storage. De-cellularization 
can be done in a centralized facil-
ity, as the organic matrix that will 
be obtained can be donated to any 
patient. For this part of the pro-
cess the logistics and economies 
of scale suggest that a centralized 
manufacturing approach would 
be feasible. However, the autolo-
gous part of the process, collecting 
cells from the patient and grow-
ing them in a locally distributed 
manufacturing facility, presents 
the same challenges as discussed in 
‘The links between manufacturing 
systems and distribution models’ 
section. In this case, the situation 
becomes more complicated be-
cause the seeded biomatrix is sur-
gically inserted into the patient; 
increasing the number of actors 
that need to collaborate and align 
their processes in order to deliver 
tissue regeneration therapy. 
Another interviewee reported 
that there is a need for co-evolution 
of processes, techniques and tech-
nologies between the clinical setting 
and the RM manufacturer, especial-
ly in the area of tissue regeneration 
as follows [Figure 3]:
“When a patient has 
been identified from the 
clinical setting, there is 
cell-harvesting leading to 
cell culture/multiplication in 
a cGMP certified plant; re-
cellularization of the matrix 
and surgery and recuperation 
of patient; all these activities 
need to co-evolve to allow 
adoption of an innovation.” 
– Founder of a Tissue 
Regeneration Firm
Particularly in the allogene-
ic cases we studied, shelf life was 
identified as a key component, 
and this is closely linked to cryo-
preservation technology which, as 
respondents reported, needs to be 
improved to ensure cell or tissue 
viability after storage for long pe-
riods. These aspects are important 
for effective handling of the phar-
macy procedures in the hospitals. 
DISCUSSION & 
CONCLUSIONS
We propose that understanding of 
the distinction between disruptive 
and incremental innovation, and 
of the nature, extent and location 
of the disruption across sectoral 
value chains, can help to guide 
company innovation strategies and 
government innovation support 
policies for RM, as already pro-
posed for industrial biotechnology 
[17]. The RM-related disruption 
for pharmaceutical industry busi-
ness models comes on top of an 
earlier phase of disruption caused 
by biopharmaceuticals (large pro-
tein molecules and monoclonal an-
tibodies) that had already begun to 
re-shape the sector [22–24] and so 
to some extent paved the way for 
RM. However, RM imposes addi-
tional disruption on pharmaceuti-
cal and biopharmaceutical business 
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models to the extent that it has 
taken a decade of intensive intel-
lectual and commercial investment 
to reach a stage where the small 
number of products that have been 
approved often under-perform and 
are withdrawn, and success is de-
scribed narrowly in terms of the 
number of products in clinical 
trials [25]. Current analyses of the 
RM sector are still leading to calls 
for delivery systems designed for 
pills and biologics to be changed to 
accommodate cells [20].
Such difficulties and delays are 
more pronounced the more dis-
ruptive the technology is for the 
relevant sector. For RM therapies, 
faced with the individual disrup-
tive elements described above, new 
value chains involving large com-
panies that are new to the sector 
(e.g., Lonza, and GE Healthcare) 
and small innovative start-up 
companies are slowly beginning 
to emerge. Our analysis of the 
impacts of disruptive innovation 
includes the observation that in-
novation will proceed most rapid-
ly and effectively if it is developed 
by the sector for which it is least 
disruptive and that, for life science 
innovation, government regulato-
ry and policy decisions can make 
a transformative difference to the 
rapidity of uptake of a technology 
and the location of the innovation 
within an array of possible industry 
sectors [2]. 
The early regulatory choice 
to regulate stem cell therapies 
through the pharmaceutical regu-
latory system was one important 
factor driving the innovation tra-
jectory for this technology towards 
the large scale, centralized manu-
facture of allogeneic therapies by 
incumbent pharmaceutical com-
panies. These companies had an 
interest in the technology and the 
commercial capability to support 
its development but the extent of 
disruption of their business mod-
els has been one factor slowing and 
in some cases stalling development 
of therapies. The converse of the 
focus on pharmaceutical compa-
nies has been the relative lack of 
private sector investment in the 
development of locally distributed 
manufacture of autologous thera-
pies [1]. 
It is interesting to speculate on 
what the nature of current busi-
ness models and value chains for 
RM therapies might have been, 
given a decision to regulate RM 
therapies as medical devices rath-
er than drugs, or to focus more 
strongly on standards and less 
on regulation as the basis for en-
suring safety, quality and efficacy 
[2]. Many of the disruption-re-
lated challenges would have been 
removed or diminished, but the 
necessary private sector invest-
ment may still have been lacking. 
Under these circumstances, the 
public sector and philanthropic 
organizations often step in to fill 
the gap in translational funding 
[18], but without commercially vi-
able business models this is not a 
long-term stable solution. 
With the publication of the 
White Paper on Regulation for the 
Fourth Industrial Revolution [26] 
the UK government is embarking 
on a new approach to the gover-
nance of innovative technologies. 
This could provide a route to adap-
tation of the innovation ecosystem 
for RM therapies that would en-
able the more rapid emergence of 
a broader array of innovative busi-
ness models delivering a greater va-
riety of therapies to meet complex 
patient needs [2]. 
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